

- serotonin 2A and 1B receptors. *Int J Neuropsychopharmacol* 2013;16:279-88
78. Cooper JM, Newby DA, Whyte IM, et al. Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT receptor. *Pharmacogenomics J* 2014. [Epub ahead of print]
79. Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. *Eur Neuropsychopharmacol* 2001;11:375-80
80. Serretti A, Zanardi R, Rossini D, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. *Mol Psychiatry* 2001;6:586-92
81. Ham BJ, Lee BC, Paik JW, et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:104-7
82. Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:1279-83
83. Kato M, Wakeno M, Okugawa G, et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. *Neuropsychobiology* 2007;56:167-71
84. Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. *Int Clin Psychopharmacol* 2009;24:199-203
85. Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. *Pharmacogenet Genomics* 2008;18:495-506
86. Tsai SJ, Hong CJ, Liou YJ, et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:637-41
87. Rotberg B, Kronenberg S, Carmel M, et al. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. *J Child Adolesc Psychopharmacol* 2013;23:117-22
88. Benedetti F, Colombo C, Pirovano A, et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. *Psychopharmacology (Berl)* 2009;203:155-60
89. Benedetti F, Dallaspesza S, Colombo C, et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. *Eur Psychiatry* 2010;25:476-8
90. Tsai SJ, Gau YT, Hong CJ, et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. *J Affect Disord* 2009;113:183-7
91. Gudayol-Ferre E, Guardia-Olmos J, Pero-Cebollero M, et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. *J Affect Disord* 2013;150:1082-90
92. Arias B, Serretti A, Lorenzi C, et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. *J Affect Disord* 2006;90:251-6
93. Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. *Pharmacogenomics J* 2005;5:49-53
94. Illi A, Setala-Soikkeli E, Kampman O, et al. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. *Psychiatry Res* 2010;176:85-7
95. Ji Y, Biernacka J, Snyder K, et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. *Pharmacogenomics J* 2012;12:78-85
96. Stein DJ, Daniels WM, Savitz J, Harvey BH. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. *CNS Spectr* 2008;13:945-9
97. Araragi N, Lesch KP. Serotonin (5-HT) in the regulation of depression-related emotionality: insight from 5-HT transporter and tryptophan hydroxylase-2 knockout mouse models. *Curr Drug Targets* 2013;14:549-70
98. Bath KG, Jing DQ, Dincheva I, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. *Neuropsychopharmacology* 2012;37:1297-304
99. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003;112:257-69
100. Govindarajan A, Rao BS, Nair D, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. *Proc Natl Acad Sci U S A* 2006;103:13208-13
101. Tsai SJ, Cheng CY, Yu YW, et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. *Am J Med Genet B Neuropsychiatr Genet* 2003;123B:19-22
102. Yoshida K, Higuchi H, Kamata M, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. *J Psychopharmacol* 2007;21:650-6
103. Zou YF, Wang Y, Liu P, et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. *Neuropsychobiology* 2010;61:71-8
104. Choi MJ, Kang RH, Lim SW, et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. *Brain Res* 2006;1118:176-82

105. Alexopoulos GS, Glatt CE, Hoptman MJ, et al. BDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression. *J Affect Disord* 2010;125(1-3):262-8
106. Murphy GM Jr, Sarginson JE, Ryan HS, et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. *Pharmacogenet Genomics* 2013;23:301-13
107. Haghghi M, Salehi I, Erfani P, et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. *J Psychiatr Res* 2013;47:908-15
108. Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: electrophysiological studies in the rat brain. *Synapse* 2013;67:716-27
109. Dwivedi Y. Involvement of brain-derived neurotrophic factor in late-life depression. *Am J Geriatr Psychiatry* 2013;21:433-49
110. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. *Int J Neuropsychopharmacol* 2010;13:93-101
111. Hennings JM, Kohli MA, Czamara D, et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. *PLoS One* 2013;8:e64947
112. Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. *J Psychopharmacol* 2011;25:867-74
113. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. *Br J Pharmacol* 2012;165:289-312
114. O'Brien FE, O'Connor RM, Clarke G, et al. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. *Behav Brain Res* 2014;261:17-25
115. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:398-404
116. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. *Pharmacol Res* 2008;58:344-7
117. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. *Neuron* 2008;57:203-9
118. Sarginson JE, Lazzeroni LC, Ryan HS, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. *Pharmacogenet Genomics* 2010;20:467-75
119. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. *Mol Psychiatry* 2009;14:1105-18
120. Huang X, Yu T, Li X, et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. *Pharmacogenomics* 2013;14:1723-30
121. Lin KM, Chiu YF, Tsai IJ, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. *Pharmacogenet Genomics* 2011;21:163-70
122. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. *Ther Drug Monit* 2008;30:474-82
123. Mihaljevic Peles A, Bozina N, Sagud M, et al. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:1439-44
124. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. *PLoS One* 2008;3:e1872
125. Singh AB, Bousman CA, Ng CH, et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. *Transl Psychiatry* 2012;2:e198
126. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. *CNS Spectr* 2014;19(2):165-75
127. de Klerk OL, Nolte IM, Bet PM, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. *Pharmacogenomics J* 2013;13(4):349-53
128. Zourkova A, Slanar O, Jarkovsky J, et al. MDR1 in paroxetine-induced sexual dysfunction. *J Sex Marital Ther* 2013;39:71-8
129. Noordam R, Aarts N, Hofman A, et al. Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. *J Clin Psychopharmacol* 2013;33:546-50
130. Porcelli S, Fabbri C, Spina E, et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. *Expert Opin Drug Metab Toxicol* 2011;7:1101-15
131. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand* 2001;104:173-92
132. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. *Transl Psychiatry* 2013;3:e242
- **One of the first studies estimating the impact of pharmacogenetics on health resource utilization.**
133. Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol Psychiatry* 2002;7(Suppl 1):S71-80
134. Ampuero E, Stehberg J, Gonzalez D, et al. Repetitive fluoxetine treatment affects long-term memories but not learning. *Behav Brain Res* 2013;247:92-100

135. Catches JS, Xu J, Contractor A. Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. *Behav Brain Res* 2012;228:406-14
136. Pu M, Zhang Z, Xu Z, et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. *Pharmacogenomics* 2013;14:277-88
137. Pickard BS, Malloy MP, Christoforou A, et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. *Mol Psychiatry* 2006;11:847-57
138. Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. *Neuropsychopharmacology* 2009;34:1819-28
139. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. *Am J Psychiatry* 2007;164:1530-8
140. Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. *Psychoneuroendocrinology* 2013;38:2789-99
141. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. *Peptides* 2010;31:736-56
142. Kloiber S, Ripke S, Kohli MA, et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. *Eur Neuropsychopharmacol* 2013;23:653-62
143. Picciotto MR, Brabant C, Einstein EB, et al. Effects of galanin on monoaminergic systems and HPA axis: potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. *Brain Res* 2010;1314:206-18
144. Kuteeva E, Wardi T, Lundstrom L, et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. *Neuropsychopharmacology* 2008;33:2573-85
145. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. *Proc Natl Acad Sci U S A* 2006;103:1593-8
146. Heilig M. The NPY system in stress, anxiety and depression. *Neuropeptides* 2004;38:213-24
147. Nikisch G, Agren H, Eap CB, et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. *Int J Neuropsychopharmacol* 2005;8:403-10
148. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. *Nature* 2008;452:997-1001
149. Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. *Eur Neuropsychopharmacol* 2010;20:301-9
150. Murck H, Held K, Ziegenbein M, et al. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. *Psychoneuroendocrinology* 2004;29:1205-11
151. Unschuld PG, Ising M, Roeske D, et al. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. *Neuropsychopharmacology* 2010;35:1583-92
152. Dryden S, Brown M, King P, Williams G. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. *Horm Metab Res* 1999;31:363-6
153. Kraus T, Haack M, Schulz A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. *Pharmacopsychiatry* 2002;35:220-5
154. Fatscas M, Denis C, Lavie E, Auriacombe M. Relationship between anxiety disorders and opiate dependence – a systematic review of the literature: implications for diagnosis and treatment. *J Subst Abuse Treat* 2010;38:220-30
155. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. *Arch Gen Psychiatry* 2006;63:1199-208
156. Garriock HA, Tanowitz M, Kraft JB, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. *Am J Psychiatry* 2010;167:565-73
157. Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. *Hum Psychopharmacol* 2013;28:258-62
158. Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. *Nat Neurosci* 2006;9:1134-41
159. Dillon DG, Bogdan R, Fagerness J, et al. Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. *Hum Brain Mapp* 2010;31:210-21
160. Perlis RH, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. *Neuropsychopharmacology* 2008;33:2810-19
161. Biel M, Wahl-Schott C, Michalakis S, Zong X. Hyperpolarization-activated cation channels: from genes to function. *Physiol Rev* 2009;89:847-85
162. Nolan MF, Malleret G, Dudman JT, et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. *Cell* 2004;119:719-32
163. Lewis AS, Vaidya SP, Blais CA, et al. Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. *J Neurosci* 2011;31:7424-40
164. Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic- and antidepressant-like behaviors. *Neuron* 2012;75:503-16

165. Janssen DG, Ciani RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. *Hum Psychopharmacol* 2010;25:201-15
166. Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. *CNS Neurol Disord Drug Targets* 2007;6:163-82
167. Liu Z, Zhu F, Wang G, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. *Neurosci Lett* 2007;414:155-8
168. Licinio J, O'Kirwan F, Irizarry K, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. *Mol Psychiatry* 2004;9:1075-82
169. Papiol S, Arias B, Gasto C, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. *J Affect Disord* 2007;104:83-90
170. Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. *Arch Gen Psychiatry* 2010;67:369-79
171. Brouwer JP, Appelhof BC, van Rossum EF, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. *Psychoneuroendocrinology* 2006;31:1154-63
172. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response—an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. *Biol Psychiatry* 2008;63:1103-10
173. Ellsworth KA, Moon I, Eckloff BW, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. *Pharmacogenomics* 2013;23:156-66
174. Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. *Am J Psychiatry* 2010;167:190-7
175. Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. *Neuropsychopharmacology* 2013;38:377-85
176. Yu YW, Chen TJ, Hong CJ, et al. Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response. *Neuropsychopharmacology* 2003;28:1182-5
177. Tadic A, Rujescu D, Muller MJ, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. *Neuropsychiatr Dis Treat* 2008;4:269-76
178. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. *Am J Hum Genet* 2007;80:531-8
179. Shen X, Carlborg O. Beware of risk for increased false positive rates in genome-wide association studies for phenotypic variability. *Front Genet* 2013;4:93
- **Study that provides an interesting discussion about one of the major limitations of GWAS.**
180. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. *Biol Psychiatry* 2010;67:133-8
- **The largest GWAS investigating the pharmacogenetics of SSRIs.**
181. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. *Am J Psychiatry* 2010;167:555-64
- **One of the main GWAS investigating antidepressant response.**
182. Crumbley C, Wang Y, Kojetin DJ, Burris TP. Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/ROREalpha target gene. *J Biol Chem* 2010;285:35386-92
183. Perroud N, Uher R, Ng MY, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. *Pharmacogenomics* 2012;12:68-77
184. Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. *Pharmacogenomics* 2009;19:666-74
185. Holmans P. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. *Adv Genet* 2010;72:141-79
186. Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic opportunities. *Neurosci Biobehav Rev* 2013;37:109-22
187. Tansy KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. *PLoS Med* 2012;9:e1001326
- **One of the main genome-wide association study and meta-analysis of antidepressant response.**
188. Serretti A, Olgjati P, Bajo E, et al. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. *World J Biol Psychiatry* 2011;12:501-15
189. Olgjati P, Bajo E, Bigelli M, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. *Prog Neuropsychopharmacol Biol Psychiatry* 2012;36:147-54
- **Pharmacoeconomic study estimating the cost-effectiveness ratio of SLC6A4 5-HTTLPR-guided antidepressant treatment.**
190. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. *Mol Psychiatry* 1998;3:508-11
191. Zanardi R, Benedetti F, DiBella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. *J Clin Psychopharmacol* 2000;20:105-7
192. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional

- and nondelusional depression. *Biol Psychiatry* 2001;50:323-30
193. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression. *Neuropsychopharmacology* 2000;23:587-90
 194. Arias B, Catalan R, Gasto C, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. *J Clin Psychopharmacol* 2003;23:563-7
 195. Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. *Psychopharmacology (Berl)* 2004;174:525-9
 196. Serretti A, Cusin C, Rossini D, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. *Am J Med Genet B Neuropsychiatr Genet* 2004;129:36-40
 197. Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. *J Psychiatry Neurosci* 2008;33:123-30
 198. Illi A, Poutanen O, Setälä-Soikkeli E, et al. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? *Eur Arch Psychiatry Clin Neurosci* 2011;261:95-102
 199. Rausch JL, Johnson ME, Fei Y, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. *Biol Psychiatry* 2002;51:723-32
 200. Yu YW, Tsai SJ, Chen TJ, et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. *Mol Psychiatry* 2002;7:1115-19
 201. Mushtaq D, Ali A, Margoob MA, et al. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. *J Affect Disord* 2012;136:955-62
 202. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:383-6
 203. Umene-Nakano W, Yoshimura R, Ueda N, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. *J Psychopharmacol* 2010;24(12):1764-71
 204. Saeki Y, Watanabe T, Ueda M, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. *Eur J Clin Pharmacol* 2009;65:685-91
 205. Won ES, Chang HS, Lee HY, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. *Neuropsychobiology* 2012;66:221-9
 206. Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. *Pharmacogenomics J* 2002;2:176-81
 207. Ng C, Sarris J, Singh A, et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. *Hum Psychopharmacol* 2013;28:516-22
 208. Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. *Eur J Clin Pharmacol* 2011;67:1213-21
 209. Kim W, Choi YH, Yoon KS, et al. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30:1413-18
 210. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. *J Affect Disord* 2010;123:308-11
 211. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. *J Clin Psychiatry* 2007;68:747-53

Affiliation

Chiara Fabbri¹, Alessandro Minarini¹, Tomihisa Niitsu^{1,2} & Alessandro Serretti^{†1} MD PhD
[†]Author for correspondence
¹University of Bologna, Institute of Psychiatry, Department of Biomedical and NeuroMotor Sciences, Viale Carlo Pepoli 5, 40123 Bologna, Italy
 Tel: +39 051 6584233;
 Fax: +39 051 521030;
 E-mail: alessandro.serretti@unibo.it
²Chiba University Graduate School of Medicine, Research Center for Child Mental Development, Chiba, Japan

Supplementary materials available online

Figure 1.

RESEARCH ARTICLE

Repeated Exposure of Adult Rats to Transient Oxidative Stress Induces Various Long-Lasting Alterations in Cognitive and Behavioral Functions

Yoshio Iguchi, Sakurako Kosugi, Hiromi Nishikawa, Ziqiao Lin, Yoshio Minabe, Shigenobu Toda*

Department of Psychiatry and Neurobiology, Kanazawa University School of Medicine, Kanazawa, Ishikawa, Japan, 980–8641

*yiguchi@med.kanazawa-u.ac.jp



 OPEN ACCESS

Citation: Iguchi Y, Kosugi S, Nishikawa H, Lin Z, Minabe Y, et al. (2014) Repeated Exposure of Adult Rats to Transient Oxidative Stress Induces Various Long-Lasting Alterations in Cognitive and Behavioral Functions. *PLoS ONE* 9(12): e114024. doi:10.1371/journal.pone.0114024

Editor: Thomas H. J. Burne, University of Queensland, Australia

Received: July 11, 2014

Accepted: November 4, 2014

Published: December 9, 2014

Copyright: © 2014 Iguchi et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by Grants-in-Aids from the Ministry of Education, Culture, Sports and Technology, Japan (20452097 and 25860994 to YI; 24791208 to SK; 26860920 to HN; 25461727, 25116510, and 26120712 to ST), Eli Lilly (to YI), Japan Foundation for Neuroscience and Mental Health (to YI), Takeda Research Foundation (to ST) and Matsubara Saburoh Memorial Research Foundation for Psychiatry (to SK, ZL and YI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have received funding from a commercial source, Eli Lilly. However, the authors declare that this does not alter their adherence to all PLOS ONE policies on sharing data and materials.

Abstract

Exposure of neonates to oxidative stress may increase the risk of psychiatric disorders such as schizophrenia in adulthood. However, the effects of moderate oxidative stress on the adult brain are not completely understood. To address this issue, we systemically administrated 2-cyclohexen-1-one (CHX) to adult rats to transiently reduce glutathione levels. Repeated administration of CHX did not affect the acquisition or motivation of an appetitive instrumental behavior (lever pressing) rewarded by a food outcome under a progressive ratio schedule. In addition, response discrimination and reversal learning were not affected. However, acute CHX administration blunted the sensitivity of the instrumental performance to outcome devaluation, and this effect was prolonged in rats with a history of repeated CHX exposure, representing pro-depression-like phenotypes. On the other hand, repeated CHX administration reduced immobility in forced swimming tests and blunted acute cocaine-induced behaviors, implicating antidepressant-like effects. Multivariate analyses segregated a characteristic group of behavioral variables influenced by repeated CHX administration. Taken together, these findings suggest that repeated administration of CHX to adult rats did not cause a specific mental disorder, but it induced long-term alterations in behavioral and cognitive functions, possibly related to specific neural correlates.

Introduction

Stressors evoke various adaptive or maladaptive responses in individuals that may strengthen or weaken their response, respectively, to forthcoming stress in the near or distant future [1–2]. Many psychiatric disorders of humans, such as schizophrenia, major depression, posttraumatic stress disorder, and drug addiction, can be triggered, reversed, or exacerbated when there is unexpected excessive exposure to diverse stressors or when individuals are vulnerable to these stressors [3–5].

A traditional approach to study stress-induced psychiatric disorders was to investigate the relationship between each stressor and each evoked phenotype or pathophysiological response (e.g., social defeat stress and depression). However, one major pitfall of this strategy is the difficulty of dealing with the diversity of stress and the redundancy of its outcome. Humans or animals are often simultaneously exposed to various stressors that generate overlapping responses that are difficult to distinguish from each other. For example, fatigue is generally considered a hallmark of physical stress, but it can be induced by psychological stresses, including social defeat. Depressive mood can be induced by both social defeat and lack of sleep. In addition, a stressor induces various signaling responses (including the hypothalamic–pituitary–adrenal axis, inflammatory reactions, oxidative stress, and the redox system), which mediate stressors and pathological and/or adaptive phenotypes but evoke intertwined biochemical interactions among them [6]. As a result, the relationship between a cause (stressor) and an outcome (symptom or phenotype) is extremely complicated and far from stoichiometric.

To study the roles of stress in animal models of psychiatric disorders in a simplified manner, we used oxidative stress. Oxidative stress has been proposed as a major intracellular mediator for most primary stressors, including physical stress [7] or social stress [8], and it induces relatively characterized and quantifiable biochemical reactions [9]. The relevance of oxidative stress has been repeatedly demonstrated in both clinical and preclinical studies. For example, prenatal or neonatal exposure to oxidative stress caused by infection or a lack of a redox system is proposed to increase the risk of schizophrenia in adolescents [10–11]. However, in cases of major depression or drug addiction, critical exposure to oxidative stress may occur in adolescence or adulthood. Thus, the pathological significance of oxidative stress in adulthood must be completely addressed by both preclinical and clinical studies.

A promising approach for studying the relevance of oxidative stress to brain functions is to utilize animals lacking genes encoding enzymes required for glutathione synthesis because glutathione is one of the most abundant antioxidants in the body [12–13]. One of the most representative molecules causing oxidative stress, reactive oxygen species (ROS), is continuously generated in the brain, which consumes more oxygen than other organs (approximately 20% in the resting state), and the concentration of glutathione in the organs is tightly regulated to counterbalance ROS generation [14]. Thus, any manipulation to

reduce glutathione will result in an immediate imbalance of the equilibrium between ROS production and anti-oxidative systems, leading to an immediate increase in ROS. However, using this genetic tool, it is extremely difficult to mimic intermittent stress loading that animals typically encounter in the natural world, and a constitutive non-physiological decrease in glutathione levels may induce stronger neurotoxicity that may cause a neurodegenerative disease-like, rather than a neuropsychiatric disease-like, condition. It is also difficult to distinguish between the direct and indirect effects of oxidative stress (e.g., the consequence of an oxidative stress-induced redox reaction) because of the inability to observe sequential alterations that occur after exposure to stress.

Therefore, in this study, we used a pharmacological method that directly induces moderate and intermittent oxidative stress accompanied by minimal concomitant psychological and physical stress. Among several pharmacological approaches to reduce glutathione in animals [15], 2-cyclohexen-1-one (CHX) binds and enhances the rapid degradation of glutathione and temporally reduces the level of glutathione. In addition, CHX can be systemically administered to subjects. Moreover, the pharmacological depletion of glutathione is an established method used to investigate the effect of glutathione on memory performance in the Morris water maze test, suggesting a relevant role of redox balance in cognition [16].

However, the effect of a minimal dose of CHX on the behavior and cognition of adult rodents, particularly when administered repeatedly, remains almost unknown, except a few studies [17]. In this study, we administered CHX acutely or repeatedly to adult rats to investigate the effects of repeated mild, rather than severe, oxidative stress exposure on behavioral or cognitive functions that are primarily mediated by the mesocorticolimbic dopamine (DA) system. The reason why we focused on the system was that this system plays a pivotal role in both the process of decision-making in healthy animals/humans [18] and the pathophysiology of schizophrenia, major depression, and drug addiction [19–20]. In addition, it is vulnerable to oxidative stress [21]. We aimed to identify a specific neural correlate that is sensitive to oxidative stress by employing various behavioral and cognitive tasks and clarify whether this type of exposure to oxidative stress would impair various neural functions in a uniform manner. We report that repeated CHX administration did not necessarily induce a certain type of DA-related mental disorder, but it altered several major variables that appeared to be primarily regulated by the DA system.

Materials and Methods

Animals

All protocols for animal care and experimentation followed the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, June 2006), and they were approved by the Kanazawa University Institutional Animal Care and Use Committee (Permit Number: AP-132850). Male Sprague–Dawley rats

(Japan SLC, Hamamatsu, Japan) 60–65 days of age that weighed 275–300 g at the start of the experiments were used. During behavioral experiments, the rats were housed individually in Plexiglas cages (38 cm × 33.5 cm × 17 cm). For biochemical experiments, the animals were housed in groups of 2–3 in identical cages. These home cages were located in a climate-controlled vivarium with a 12-h/12-h light/dark cycle, and all experimental procedures were conducted during the light cycle (between 8:45 and 20:45 h). All surgeries were performed under ketamine hydrochloride and xylazine hydrochloride anesthesia, and all efforts were made to minimize suffering.

Apparatus

Instrumental training and testing were conducted in three operant chambers (30 cm × 24 cm × 25 cm; Med Associates, St. Albans, VT, USA) located in a soundproof room. Each chamber was equipped with a dispenser that delivered a 45-mg food pellet (BioServ, Frenchtown, NJ) into a recessed magazine, and a miniature solenoid-activated valve was used to deliver 0.1 ml of a 20% sucrose solution into the magazine. Two retractable levers were located on both sides of the magazine. Illumination of the operant chamber was provided by a single 100 mA incandescent bulb located on the top center of the wall opposite of the levers. Microcomputers equipped with MED-PC software (Med Associates) controlled and recorded behaviors. For outcome devaluation tests, three Plexiglas cages (38 cm × 33.5 cm × 17 cm) with floors covered by wood chips served as the outcome consumption context, and they were placed in the room for instrumental training. Cocaine-induced behaviors were monitored using three photoelectric actimeters (Panlab, Barcelona, Spain). Each actimeter comprised an open field constructed of transparent acrylic plastic (45 cm × 45 cm × 30 cm) under faint illumination (approximately 0.5 lx) with a wood chip-covered floor and two planar square frames in which 16 × 16 infrared beams were arranged to surround the open field. When an animal in the open field interrupted the beams, its location and movements were revealed (5 Hz polling rate). ActiTrack software (Panlab, Holliston, MA, USA) was used to analyze the locomotion, rearing, and stereotyping scores. The forced swimming test employed a glass cylinder (52 cm height × 24 cm diameter) filled with water (24 ± 1 °C) to a depth of 26 cm.

Procedure

Instrumental learning

Training on a time-constraint progressive ratio (PR) schedule. Seven days before conducting the behavioral procedures, rats were handled daily and placed on a food-deprivation schedule to maintain them at approximately 85% of their *ad libitum* feeding body weight. They had free access to water in their home cage. The animals (N=34) were trained with food pellet and sucrose outcomes. One outcome was delivered dependent on lever pressing, whereas another outcome was delivered indifferent to lever pressing (lever press-non-contingent outcome);

the latter served as the control condition for the outcome devaluation test. The contingency between the outcome (pellets/sucrose) and the lever used in training (left/right) was counterbalanced among the animals. After two daily 30-min initial training sessions, including apparatus habituation and magazine training, the rats were manually trained with a specific lever with the lever press-contingent outcome (Days -6 to -4). Then, they received three daily training sessions, first on a fixed ratio (FR) of 1, then on an FR-2, and finally on an FR-5 schedule (Days -3 to -1). Each session lasted until the rat received 50 outcomes. After the FR training, the animals underwent daily training sessions on a PR schedule for 7 consecutive days (Days 1-7). The PR schedule was based on exponential progression as follows: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, etc., calculated using the formula $(5 \times e^{0.2n}) - 5$, rounded to the nearest integer, where n is the position in the sequence of the ratio [22]. Each 60-min daily session began with turning on the light and inserting the lever. The session ended with retracting the lever and turning off the light. The lever press-non-contingent outcome was delivered on a variable time schedule that averaged every 180 s (approximately 20 outcomes were delivered in a 60-min period). A delay prevented this outcome from being delivered within 3 s of each lever press.

Outcome devaluation test. Four outcome devaluation tests were conducted after PR training. Devaluation test 1 commenced 24 h after the last PR training session (Days 8 and 9, N=34). On each test day, the animals were allowed to consume *ad libitum* either the lever press-contingent (devalued condition) or non-contingent outcome (non-devalued condition) for 1 h in the outcome consumption context as follows: the animals received 25 g of pellets in a metal bowl or 150 ml of sucrose solution in a bottle. Immediately after this feeding period, the animals underwent a 10-min test in extinction with the training lever available. The order of the devalued and non-devalued conditions was counterbalanced across the experimental groups. Around half of the animals (N=18) were administered a similar devaluation test 13 days after the last PR training session (test 2, Days 20 and 21). Follow-up devaluation tests were administered to the remaining animals (N=16) 6 (test 3, Days 13 and 14) and 11 days (test 4, Days 18 and 19) after the last PR training session. No experimental treatment was administered to animals between these tests. The schedules for instrumental training, the devaluation tests, as well as other behavioral tests are depicted in Fig. 1A.

Response discrimination training and reversal. We assessed the acquisition of response discrimination and its reversal learning of the animals subjected to devaluation test 2 (N=18). The training commenced on the day following devaluation test 2 and lasted for 5 days (Days 22-26); the procedures are described in S1 Text.

Cocaine-induced behaviors

Following the instrumental learning sessions, the food-restriction schedule was discontinued, and animals had free access to food and water in their home cage (Day 26). On Day 32, the day before an acute cocaine administration, each animal




Fig. 1. Effects of repeated 2-cyclohexen-1-one (CHX) administration on motivation and behavioral flexibility in an instrumental learning. (A) Time course, 7-day time-constraint progressive ratio (PR) instrumental training and outcome devaluation tests. Animals (N=34) were injected with CHX (25 mg/kg, i.p.) or vehicle 60 min before the start of each training session. (B) The mean number of lever presses (corresponding completed ratio) on PR training. (C–F) Mean response rates (lever presses/min) during the non-devalued versus the devalued condition of the devaluation tests normalized to the response rate of the last day of PR training (C: N=34, D: N=18, E & F: N=16). Data represent the mean \pm SEM. # p <0.005, ## p <0.001 compared with the non-devalued condition.

doi:10.1371/journal.pone.0114024.g001

(N=18) was acclimated to the open field of the actimeter for 1 h. On the next day (Day 33), each rat was placed into the open field for 30 min to determine the baseline levels of behaviors without injection. After the 30-min period, each animal received cocaine (15 mg/kg, intraperitoneally [i.p.]), and it was placed in the open field for 120 min. In each session, infrared beams detected horizontal motor activity (distance traveled in cm), rearing (vertical activity over 14 cm), and stereotypy (number of samples where the position of animal was different from its position during the previous sample and equal to its position during the 2nd sample back in time).

Forced swimming test

On Day 42, animals (N=18) were individually placed for 15 min in a glass cylinder containing water. The water was changed after each session, and the

cylinder was cleaned to eliminate the possible influence of alarm pheromones left behind by previous animals. The behaviors of the animals were recorded using a video camera (HDR-CX560, Sony, Tokyo, Japan) and analyzed by a trained observer uninformed of the experimental design to rate the behavior as immobility or mobility at the end of each 5-s interval. Immobility was defined as no additional activity other than that required maintaining the rat's head above water with at least three of the rat's paws being immobile [23]. Mobility was defined as climbing, swimming, and diving. The immobility ratio was determined as the ratio of immobility behaviors to the sum of immobility plus mobility behaviors.

Drugs

CHX (Sigma-Aldrich, St. Louis, MO, USA) was diluted with 0.9% saline and i.p. administrated at 12.5, 25, and 50 mg/kg of body weight to determine glutathione levels in the brain. For behavioral experiments, a dose of 25 mg/kg CHX (for Group CHX) or saline (for Group Veh) was administrated 60 min before each session of the 7 days of PR training. *N*-acetylcysteine (Sigma-Aldrich) was dissolved in saline and i.p. administrated at a dose of 1 g/kg. For outcome devaluation test 3, all animals were injected with CHX at a dose of 25 mg/kg 60 min before the test (i.e., the *ad-lib* outcome consumption start point). Cocaine hydrochloride (Takeda Pharmaceutical Co., Japan) dissolved in saline was i.p. administrated at a dose of 15 mg/kg.

Statistical analyses

The numbers of lever presses by animals that received repeated CHX pretreatment (Group CHX) and those that received vehicle (Group Veh) during the 7-day PR training sessions were compared using two-way repeated measures analysis of variance (ANOVA). Because the inter-individual difference in lever presses during PR training (i.e., baseline performance for outcome devaluation tests) was not negligible, we utilized the response rate for the first 10-min period on the last day of the PR training to normalize the data for the 10-min devaluation tests. Two-way repeated measures ANOVA (Group \times Value of outcome: non-devalued vs. devalued) was used to evaluate the scores. Animal behaviors in the actimeter (distance traveled and the numbers of rearing and stereotypy behaviors) were recorded at 5-min intervals and analyzed using two-way repeated measures ANOVA. Simple main effect tests were performed as *post hoc* group comparisons when indicated by a significant interaction between factors. One-way ANOVA was used to analyze the immobility ratio of the forced swimming test. The aforementioned statistical analyses were performed using ANOVA 4 on the web (<http://www.hju.ac.jp/~kiriki/anova4>). The Pearson correlation coefficients (*r*) between the principal behavioral measures and *t*-tests for the correlation coefficients were analyzed using GraphPad Prism ver. 5.04 software (Graph Pad Software Inc., San Diego, CA, USA) with Bonferroni's method for correction of

multiple tests. This software was also used for the analyses of biochemical experiments, one- or two-way ANOVAs, and subsequent multiple comparisons by using Student's *t*-test. Principal component analysis (PCA) of the behavioral measures and subsequent *t*-tests (corrected with Bonferroni's method) for the group differences of each principal component (PC) score were performed using R ver. 2.15.3 software [24]. The reliability of all statistical tests was assessed against a type I error rate (α) of 0.05.

Results

Optimization of the CHX dose for behavioral experiments to minimize drug-induced neurotoxicity

Before determining the effect of acute or repeated CHX administration on various behaviors, we determined the most appropriate dose of CHX (S1 Text). First, we administered varying doses of CHX i.p. to rats and determined the effect of CHX on the glutathione concentration in the nucleus accumbens (NAc). The concentration of glutathione in the NAc or dorsal striatum (dSt) of the control animals administered saline was approximately 30–40 nmol/mg, nearly compatible with previous reports that employed similar methods [25–26], and there was no significant difference between these two regions (data not shown). Acute administration of 12.5 mg/kg CHX did not detectably reduce glutathione levels, whereas CHX doses ≥ 25 mg/kg induced a significant reduction in total glutathione levels in the NAc, confirming a dose-dependent effect of CHX on total glutathione levels (one-way ANOVA, $F[3, 14] = 73.61$, $p < 0.001$; *post hoc t*-test, saline vs. CHX 25 mg, $p < 0.001$; saline vs. CHX 50 mg, $p < 0.0001$; CHX 12.5 mg vs. CHX 25 mg, $p < 0.01$; CHX 12.5 mg vs. CHX 50 mg, $p < 0.0001$; CHX 25 mg vs. CHX 50 mg, $p < 0.0001$; Figure A in S1 Figure). This effect was blocked by an excess amount of the precursor of cysteine, *N*-acetylcysteine (1 g/kg, i.p.) (one-way ANOVA, $F[2, 11] = 6.367$, $p < 0.05$; *post hoc t*-test, saline vs. CHX, $p < 0.05$; CHX vs. CHX + NAC, $p < 0.05$; Figure B in S1 Figure). As the supply of cysteine (or *N*-acetylcysteine) is the rate-limiting factor in glutathione synthesis in astrocytes [27], this result further confirmed the expected effect of CHX on total glutathione levels.

We next determined the effect of 25 mg/kg CHX on glutathione turnover. In the NAc, the effect of acute CHX administration was restored after 3 h (one-way ANOVA, $F[2, 11] = 4.62$, $p < 0.05$; *post hoc t*-test, saline vs. CHX 1 h, $p < 0.05$; Figure C in S1 Figure). In contrast, in the dSt, the effect of CHX was detected at 3 h but not 1 h after CHX administration (one-way ANOVA, $F[2, 12] = 5.75$, $p < 0.05$; *post hoc t*-test, saline vs. CHX 3h, $p < 0.05$; Figure D in S1 Figure), suggesting a region-specific difference in glutathione turnover. In consistent with the acute effect of CHX, consecutive CHX administration for 7 days altered the glutathione levels of the dSt, but not of the NAc, versus baseline 24 h after the last CHX session (*t*-test; NAc, $p = 0.9156$; dSt, $p = 0.0143$; Figure E in S1 Figure). However, after a 3-week withdrawal period, there was no significant effect of

previous CHX administration on the glutathione levels of the NAc or dSt (*t*-test: NAc, $p=0.9856$; dSt, $p=0.9757$; Figure F in [S1 Figure](#)).

We then determined whether the administration of 25 mg/kg CHX induced neural cell apoptosis by conducting *in situ* assays of TdT-mediated dUTP-biotin nick end labeling (TUNEL) in the dSt and NAc using kainic acid-induced apoptosis as the positive control ([S1 Text](#)). Microinjection of kainic acid into the dSt of naïve rats induced robust TUNEL signals as expected, whereas in the animals that were repeatedly administrated CHX, TUNEL signals were undetectable in the dSt or NAc on the day following the last CHX administration ([S2 Figure](#)). Accordingly, we used a CHX dose of 25 mg/kg for behavioral studies because this dose was appropriate for minimizing the adverse effects of CHX, such as prolonged reduction in glutathione levels or apoptosis.

Effect of repeated CHX administration on instrumental learning

CHX pretreatment and time-constraint PR instrumental training

An appetitive instrumental performance trained under a PR schedule has been widely used for investigating the acquisition process of reward-seeking and the motivation required for the learning [28]. By employing this strategy, we first investigated the effect of CHX administrated 60 min before each training session on these two factors, which are essential for effort-based reinforcement learning. Animals readily acquired the PR task from the first training session, and there was no obvious variation in the PR performance without any significant group difference during the seven sessions ([Fig. 1B](#)). Although we defined the breakpoint as the last ratio measured before 5 min elapsed without any lever press, this breakpoint criterion was not met in most cases. An ANOVA (2 [Group: Vehicle vs. CHX] \times 7 [Session]) did not indicate significant main effects (Group: $F[1, 32]<1$; Session: $F[6, 192]<1$) or interactions ($F[6, 192]=1.02$).

Outcome devaluation tests after 7 days of PR training

The learning and performance of an instrumental behavior are balanced between two distinct mutually competing processes called goal-directed and habitual processes [29–33]. In addition, the sensitivity of instrumental performance to outcome devaluation is widely used as an index to distinguish goal-directed process from habitual process. In short, as long as an instrumental performance is sensitive to outcome devaluation, it is goal-directed; otherwise, it is habitual [29–33]. To examine whether lever-pressing performance trained with CHX pretreatment is goal-directed or habitual, we evaluated the sensitivity of the animals to outcome devaluation induced by outcome-specific satiation. The devaluation tests performed immediately (test 1; [Fig. 1C](#)) and 13 days after the last PR training (test 2, [Fig. 1D](#)) revealed significant sensitivities of the instrumental performance for outcome devaluation in both groups. ANOVAs (2 [Group: Vehicle vs. CHX] \times 2 [Value: non-devalued vs. devalued]) revealed a significant main effect of Value for test 1 ($F[1, 32]=45.78$, $p<0.001$) and 2 ($F[1, 16]=49.00$, $p<0.001$).

Outcome devaluation tests with CHX challenge

Next, we determined whether acute administration of CHX would alter the effect of outcome devaluation in both groups. The first devaluation test (test 3, 6 days after the last PR session) was performed 60 min after a CHX injection (Fig. 1E), and the second devaluation test was performed 4 days after test 3 for the same animals to await CHX washout. Test 4 was performed without any CHX administration to determine whether the previous CHX administration induced any long-term effect (Fig. 1F). An ANOVA for test 3 (2 [Group: Veh vs. CHX] \times 2 [Value]) did not indicate significant main effects (Group: $F[1, 14]=1.56$; Value: $F[1, 14]=2.86$) or interaction ($F[1, 14]=1.67$). However, a similar ANOVA for test 4 revealed a significant interaction between the factors ($F[1, 14]=6.78$, $p<0.05$). In addition, a significant simple main effect of Value was revealed in Group Veh ($F[1, 14]=10.15$, $p<0.01$). In contrast, the animals in Group CHX did not respond differently to the two Value conditions ($F[1, 14]<1$).

Response discrimination training and reversal

To assess the effect of CHX on flexible behavior in response to changing environmental contingencies, we analyzed the acquisition of response discrimination and learning of its reversal (S1 Text). For the initial discrimination, the animals were trained to consistently press a particular lever between two (left or right) until they reached a criterion of eight consecutive correct choices. On the following day, the animals were trained to press the other lever. Repeated CHX administration did not affect the initial response discrimination or reversal learning (S3 Figure).

Effect of repeated CHX administration on acute cocaine-induced behaviors

We examined the effects of repeated CHX pretreatment during the 7-day PR training sessions on cocaine-induced behaviors at 26 days after the last CHX administration. Although a single dose of cocaine markedly increased locomotor activity, rearing, and stereotypy for Groups Veh and CHX, repeated CHX administration attenuated these cocaine-induced behaviors (Fig. 2A-2C). An ANOVA (2 [Group: Veh vs. CHX] \times 24 [Time bin]) for locomotor activity indicated significant main effects of Group ($F[1, 16]=4.81$, $p<0.05$) and Time bin ($F[23, 368]=32.51$, $p<0.001$), along with a significant interaction between the factors ($F[23, 368]=3.02$, $p<0.001$; Fig. 2A). ANOVAs for rearing and stereotypy indicated significant main effects of Time bin (for rearing, $F[23, 368]=13.09$, $p<0.001$; for stereotypy, $F[23, 368]=33.30$, $p<0.001$) and significant interactions between the factors (for rearing, $F[23, 368]=1.81$, $p<0.05$; for stereotypy, $F[23, 368]=1.89$, $p<0.01$; Fig. 2B-2C). CHX exerted a significant effect on open-field behaviors during the precocaine injection period (Fig. 2A). An ANOVA (2 [Group] \times 6 [Time bin]) for locomotor activity during the precocaine period revealed a significant main effect of Time bin ($F[5, 80]=66.95$, $p<0.001$) and a significant interaction between factors ($F[5, 80]=2.35$, $p<0.005$). A subsequent




Fig. 2. Effects of repeated 2-cyclohexen-1-one (CHX) administration on behavioral responses to an acute cocaine injection. (A) Locomotor activity (distance traveled in cm), (B) number of rearings, and (C) number of stereotypic movements before and after an acute injection of cocaine (15 mg/kg intraperitoneally; arrow). The test was conducted 26 days after repeated CHX or vehicle administration (N=9/each). Data represent the mean \pm SEM. * p <0.05, ** p <0.01, # p <0.005, ## p <0.001 compared with control (Veh).

doi:10.1371/journal.pone.0114024.g002

simple main effect test revealed that during the first 5 min, the animals in Group CHX traveled more than those in Group Veh ($F[1, 96]=7.75, p<0.01$). Similar ANOVAs on rearing and stereotypy during the precocaine period indicated only significant main effects of Time bin (for rearing, $F[5, 80]=40.44, p<0.001$; for stereotypy, $F[5, 80]=51.29, p<0.001$; Fig. 2B-2C). The behaviors during 1-h acclimation sessions on one day before acute cocaine administration did not

display any significance group differences (ANOVAs, 2 [Group] \times 12 [Time bin]; main effect or interactions, $F < 1.72$; [S4 Figure](#)), excluding the main effects of Time bin ($F_{s[11, 176]} = 79.77, 121.16, \text{ and } 43.87, p < 0.001$, for locomotor activity, rearing, and stereotypy, respectively).

Effect of repeated CHX administration on the forced swimming test

The effect of repeated CHX administration on immobility induced by forced swimming was assessed 35 days after the last CHX administration. Repeated CHX administration significantly reduced immobility (one-way ANOVA [Group: Vehicle vs. CHX], $F_{[1, 16]} = 6.39, p < 0.05$; [Fig. 3](#)).

Effect of repeated CHX administration on body weight

Repeated CHX administration did affect body weight during the food restriction and subsequent *ad libitum* feeding periods ([S5 Figure](#)).

Multivariate analyses through behavioral variables

To clarify the relationships between the numerous behavioral variables of the two groups and to study the putative neural substrates underlying alterations induced by CHX, we performed principal component analyses (PCAs). [S1 Table](#) shows the matrix of Pearson's correlation coefficients between all 19 behavioral variables described previously for the vehicle- and CHX-treated animals ($N = 9$ each). Based on the correlation matrix, we first conducted a preliminary PCA to extract the principal behavioral variables and identified 6 principal components (PCs) with eigenvalues > 1 consolidated from the 19 variables, representing 84.6% of the variability (data not shown). We then selected 15 variables with contributions of loading exceeding 0.80 as the principal behavioral variables for secondary PCA, which was conducted with more stringent criteria. The 15 behavioral variables were consolidated into 5 PCs with eigenvalues > 1 , representing 84.7% of the variability ([Table 1](#)).

PCs I, II, III, IV, and V accounted for 30.0%, 20.5%, 13.1%, 11.2%, and 9.8% of the variance, respectively. For PC I, positively loading behavioral variables with contributions exceeding 0.50 (absolute value) represented spontaneous behaviors in the open field, locomotion, rearing, and stereotypy, suggesting that PC I is likely related to motor functions. For PC II, the behavioral variables loading negatively were the response rate in the devalued condition of devaluation test 1 and the open-field activity prior to acute cocaine injection, whereas the positively loaded variables corresponded to the open-field activity after acute cocaine administration and the immobility ratio in forced swimming test ([S6 Figure](#)). PC III was negatively loaded by the number of perseverative errors in reversal learning and the immobility ratio. PC IV was positively loaded by the number of lever presses in the final PR training and the number of regressive errors in reversal learning and negatively loaded by the response rate in the devalued condition of




Fig. 3. Effects of 2-cyclohexen-1-one (CHX) on immobility during the forced swimming test. The test was conducted 35 days after repeated CHX or vehicle administration control (N=9/each). Data represent the mean + SEM. **p*<0.05 compared with control (Veh).

doi:10.1371/journal.pone.0114024.g003

Table 1. Results of principal component analysis of 15 principal behavioral variables.

Behavioral variable	Principal components					Contribution
	I	II	III	IV	V	
Prg 7	-0.286	-0.208	-0.575	0.558	-0.113	0.780
Dvl 1 (non-dev)	-0.134	-0.128	0.434	0.354	0.698	0.836
Dvl 1 (dev)	0.081	-0.615	0.201	-0.551	0.347	0.849
Dvl 2 (non-dev)	0.439	0.081	0.309	0.433	0.573	0.810
Rv psv er	0.288	-0.199	-0.655	0.388	0.354	0.827
Rv rgr er	0.235	-0.378	0.485	0.509	-0.418	0.867
Nvl dst	0.864	0.085	0.020	-0.288	0.127	0.853
Nvl str	0.794	-0.096	-0.130	-0.234	-0.076	0.717
Precoc dst	0.641	-0.703	-0.172	-0.167	0.026	0.963
Precoc r	0.616	-0.521	0.143	0.290	-0.322	0.859
Precoc str	0.624	-0.642	-0.284	-0.020	0.033	0.884
Postcoc dst	0.696	0.653	0.007	0.061	0.152	0.937
Postcoc r	0.756	0.355	0.209	0.297	-0.226	0.881
Postcoc str	0.620	0.648	0.171	-0.095	-0.115	0.856
Im	0.255	0.524	-0.657	-0.007	0.103	0.782
Eigenvalue	4.499	3.068	1.971	1.687	1.474	
Contribution	0.300	0.205	0.131	0.112	.098	
Contribution (cumulative)	0.300	0.504	0.636	0.748	.847	

Notes: Factor loadings exceeding 0.50 (absolute value) are shown in bold. Prg = progressive ratio instrumental training; Dvl = response rate during the outcome devaluation test; non-dev = non-devalued condition; dev = devalued condition; Rv psv er = number of perseverative errors in reversal training; Rv rgr er = number of regressive errors in reversal training; Nvl = activity monitoring in a novel environment; Precoc = period prior to acute cocaine administration; Postcoc = period after acute cocaine administration; dst = distance traveled; r = number of rearing; str = number of stereotypy; Im = immobility ratio in forced swimming test.

doi:10.1371/journal.pone.0114024.t001

devaluation test 1. PC V was positively loaded by the response rates in the valued condition of devaluation tests 1 and 2.

Finally, we analyzed the PC scores that were calculated for individuals in Groups Veh and CHX on the basis of loadings derived from PCA (S2 Table). Multiple unpaired *t*-tests with Bonferroni's correction revealed that the scores for PCs I, III, IV, and V were similar between the two groups (the largest; $t_{[16]}=1.08$). In contrast, the scores for the animals in Group CHX were significantly lower for PC II than those for animals in Group Veh ($t_{[16]}=2.96$, $p0.05$; Fig. 4).

Discussion

In the present study, we found that acute or repeated CHX administration exerted various effects on several behavioral and cognitive functions of adult rats that were relatively short-lived or prolonged, respectively. Previous studies on acute glutathione depletion by CHX or other molecules such as buthionine sulfoximine or diethylmaleate on a Y-maze or Morris water maze task have suggested a role of glutathione homeostasis in certain learning and memory tasks [16, 34–36]. In this study, we employed a lower concentration of CHX than that employed in those studies (75 mg/kg vs. 25 mg/kg), but this concentration of CHX was sufficient to significantly reduce the levels of total glutathione in the rat NAc and dSt. In this study, we investigated the effect of repeated CHX administration on glutathione levels, but not on other indices of oxidative stress, such as ROS, directly. As mentioned in [Introduction](#), exposure to oxidative stress does not necessarily occur in a sporadic or accidental manner. ROS are endogenously present, but their effect is masked by glutathione, which is also continuously generated [14]. Thus, any alteration in total glutathione content is inevitably expected to produce a concomitant fluctuation of ROS levels, particularly in the brain, although it could be too subtle and transient to monitor. Similar to the relatively mild reduction in glutathione in the present study, it has been reported that during early postnatal period repeated administration of buthionine sulfoximine, which causes a 20% reduction in glutathione levels in the rat brain, results in many cognitive deficits in adulthood [37].

We found that repeated CHX administration increased locomotor activity compared with control during the first 5 min of the second apparatus habituation training, which was performed before cocaine was administered acutely (Fig. 2A). This finding suggests impaired spatial memory in CHX animals in line with previous reports, as the novelty-induced activity recorded on the previous day (the first habituation session) did not differ between the two groups (S4 Figure).

CHX did not appear to have any significant temporal effect on either the acquisition of instrumental behavior or the motivation to perform it because compared to Group Veh there was no alteration in the instrumental performance in Group CHX during the PR training period (Fig. 1B). Moreover, repeated CHX administration did not significantly alter the sensitivity to outcome devaluation




Fig. 4. Principal component scores derived from principal component analysis (PCA) of the behavioral variables. The scores were calculated for individual animals administrated saline or 2-cyclohexen-1-one (N=9/each) using loadings derived from PCA. Data represent the mean \pm SEM. * $p < 0.05$ (Bonferroni's corrected α -value of 0.01) compared with control (Veh).

doi:10.1371/journal.pone.0114024.g004

immediately or 13 days after the last PR session (Fig. 1C-1D). Once animals acquired the instrumental behavior in the absence of CHX pretreatment (Group Veh), acute CHX administration reduced the sensitivity to outcome devaluation, although this sensitivity was recovered after washout (Fig. 1E-1F). However, in Group CHX, the insensitivity of the instrumental performance to outcome devaluation induced by a CHX challenge was prolonged even after CHX washout (Fig. 1E-1F, Group CHX). Thus, we concluded that the insensitivity of instrumental performance to outcome devaluation was induced by the acute effect of CHX but not by the long-term effect of repeated CHX administration. However, in Group CHX, the restoring process of the original sensitivity to the outcome devaluation from the effect of CHX challenge was delayed, probably due to increased vulnerability to acute oxidative stress, another long-term effect of previous repeated exposures to oxidative stress.

In addition to general acquisition or expression, the acquisition and performance of instrumental behavior are being balanced between two distinct mutually competing intrinsic systems called goal-directed and habitual processes [29–33]. Goal-directed process consists of the formation of an association between an action and the information regarding the outcome produced by the action (i.e., sensory properties and incentive values of the outcome) and feed-forward control of action performance based on current value of the outcome. On the other hand, habitual process represents reinforcement learning between a behavior and its antecedent environmental stimuli, indifferent to outcome information, leading to stimuli-induced behavior that is insensitive to outcome devaluation. The results of the present study suggest that a single dose of CHX transiently interfered with the expression, but not the acquisition, in goal-directed process. Similar to that finding, previous studies demonstrated that a single